Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.
Noxopharm Limited has reported significant progress in its September 2025 Quarterly Activities Report, highlighting new collaborations and promising trial results. The company has signed several collaboration agreements with institutions interested in its Sofra technology platform, which is being explored for various inflammatory diseases. A US company, Tezcat Biosciences, has shown promising preclinical results using Noxopharm’s oligonucleotides in a novel drug candidate. Additionally, Noxopharm’s HERACLES clinical trial has demonstrated that its SOF-SKN treatment is safe and well-tolerated, supporting the platform’s potential in treating autoimmune diseases. The extension of convertible notes and access to government rebates further strengthen the company’s financial position.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian clinical-stage drug development company focused on advancing its proprietary Sofra technology platform. The company is involved in developing treatments for inflammatory diseases and cancer, leveraging collaborations with academic and research institutions to explore the potential of its assets.
Average Trading Volume: 150,696
Technical Sentiment Signal: Sell
Current Market Cap: A$27.18M
See more insights into NOX stock on TipRanks’ Stock Analysis page.